Список литературы

1. Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M, Vestergaard C, Seneschal J, Werfel T, Cork MJ, Kunz B, Fölster-Holst R, Trzeciak M, Darsow U, Szalai Z, Deleuran M, von Kobyletzki L, Barbarot S, Heratizadeh A, Gieler U, Hijnen DJ, Weidinger S, De Raeve L, Svensson Å, Simon D, Stalder JF, Ring J; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2717-2744. doi: 10.1111/jdv.16892. Epub 2020 Nov 17. PMID: 33205485. 2. Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, Hoetzenecker W, Knol E, Simon HU, Wollenberg A, Bieber T, Lauener R, SchmidGrendelmeier P, Traidl-Hoffmann C, Akdis CA. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016 Aug;138(2):336-49. doi: 10.1016/j.jaci.2016.06.010. PMID: 27497276. 3. Akdis M, Aab A, Altunbulakli C, Azkur K, Costa RA, Crameri R, Duan S, Eiwegger T, Eljaszewicz A, Ferstl R, Frei R, Garbani M, Globinska A, Hess L, Huitema C, Kubo T, Komlosi Z, Konieczna P, Kovacs N, Kucuksezer UC, Meyer N, Morita H, Olzhausen J, O'Mahony L, Pezer M, Prati M, Rebane A, Rhyner C, Rinaldi A, Sokolowska M, Stanic B, Sugita K, Treis A, van de Veen W, Wanke K, Wawrzyniak M, Wawrzyniak P, Wirz OF, Zakzuk JS, Akdis CA. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2016 Oct;138(4):984-1010. doi: 10.1016/j.jaci.2016.06.033. Epub 2016 Aug 28. PMID: 27577879. 4. Walker JA, McKenzie ANJ. TH2 cell development and function. Nat Rev Immunol. 2018 Feb;18(2):121-133. doi: 10.1038/nri.2017.118. Epub 2017 Oct 30. PMID: 29082915. 5. Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, Rossi AB. Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis. JID Innov. 2022 Apr 26;2(5):100131. doi: 10.1016/j.xjidi.2022.100131. PMID: 36059592; PMCID: PMC9428921. 6. Brough HA, Nadeau KC, Sindher SB, Alkotob SS, Chan S, Bahnson HT, Leung DYM, Lack G. Epicutaneous sensitization in the development of food allergy: What is the evidence and how can this be prevented? Allergy. 2020 Sep;75(9):2185-2205. doi: 10.1111/all.14304. Epub 2020 May 18. PMID: 32249942; PMCID: PMC7494573 7. Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier 66 dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017 Jul;278(1):116- 130. doi: 10.1111/imr.12546. PMID: 28658558; PMCID: PMC5492959 8. Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021 Nov;21(11):739- 751. doi: 10.1038/s41577-021-00538-7. Epub 2021 Apr 12. PMID: 33846604 9. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017 Jun;139(6):1723-1734. doi: 10.1016/j.jaci.2017.04.004. PMID: 28583445. 10. Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul 1;2(3):e24137. doi: 10.4161/jkst.24137. Epub 2013 Aug 15. PMID: 24069552; PMCID: PMC3772104. 11. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017 May;13(5):425-437. doi: 10.1080/1744666X.2017.1298443. Epub 2017 Mar 15. PMID: 28277826. 12. Kim JS. Pediatric atopic dermatitis: the importance of food allergens. Semin Cutan Med Surg. 2008 Jun;27(2):156-60. doi: 10.1016/j.sder.2008.05.003. PMID: 18620138. 13. Campana R, Dzoro S, Mittermann I, Fedenko E, Elisyutina O, Khaitov M, Karaulov A, Valenta R. Molecular aspects of allergens in atopic dermatitis. Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):269-277. doi: 10.1097/ACI.0000000000000378. PMID: 28622169; PMCID: PMC639217 14. Hradetzky S, Werfel T, Rösner LM. Autoallergy in atopic dermatitis. Allergo J Int. 2015;24(1):16-22. doi: 10.1007/s40629-015-0037-5. Epub 2015 Feb 9. PMID: 26120543; PMCID: PMC4479480 15. Ivert LU, Wahlgren CF, Lindelöf B, Dal H, Bradley M, Johansson EK. Association between atopic dermatitis and autoimmune diseases: a population-based case-control study. Br J Dermatol. 2021 Aug;185(2):335-342. doi: 10.1111/bjd.19624. Epub 2020 Dec 8. PMID: 33091150; PMCID: PMC8451742 16. Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, Tofte S, Dunn JD, Feldman SR, Clark AR, Schwartz G, Eichenfield LF. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018 Dec;19(6):821-838. doi: 10.1007/s40257-018-0383-4. PMID: 30168085. 17. Acharya P, Mathur M. Association of atopic dermatitis with vitiligo: A systematic review and meta-analysis. J Cosmet Dermatol. 2020 Aug;19(8):2016-2020. doi: 10.1111/jocd.13263. Epub 2019 Dec 24. PMID: 31872933. 67 18. Darlenski R, Kazandjieva J, Hristakieva E, Fluhr JW. Atopic dermatitis as a systemic disease. Clin Dermatol. 2014 May-Jun;32(3):409-13. doi: 10.1016/j.clindermatol.2013.11.007. Epub 2013 Nov 22. PMID: 24767188. 19. Oliveira C, Torres T. More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol. 2019 Jun 1;29(3):250-258. doi: 10.1684/ejd.2019.3557. PMID: 31122909. 20. Brunner PM, Silverberg JI, Guttman-Yassky E, Paller AS, Kabashima K, Amagai M, Luger TA, Deleuran M, Werfel T, Eyerich K, Stingl G; Councilors of the International Eczema Council. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. J Invest Dermatol. 2017 Jan;137(1):18-25. doi: 10.1016/j.jid.2016.08.022. Epub 2016 Oct 20. PMID: 27771048. 21. Schmitt J, Schwarz K, Baurecht H, Hotze M, Fölster-Holst R, Rodríguez E, Lee YAE, Franke A, Degenhardt F, Lieb W, Gieger C, Kabesch M, Nöthen MM, Irvine AD, McLean WHI, Deckert S, Stephan V, Schwarz P, Aringer M, Novak N, Weidinger S. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016 Jan;137(1):130-136. doi: 10.1016/j.jaci.2015.06.029. Epub 2015 Aug 4. PMID: 26253344. 22. Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, Rossi AB, Brignoli L, Saba G, Guillemin I, Fenton MC, Auziere S, Eckert L. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021 Apr;126(4):417-428.e2. doi: 10.1016/j.anai.2020.12.020. Epub 2021 Jan 6. PMID: 33421555. 23. Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, Margolis DJ, de Bruin-Weller M, Eckert L. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018 Jun;73(6):1284-1293. doi: 10.1111/all.13401. Epub 2018 Feb 13. PMID: 29319189. 24. Кубанов А.А., Богданова Е.В. Организация и результаты оказания медицинской помощи по профилю дерматовенерология в Российской Федерации. Итоги 2018 года. Вестник дерматологиии венерологии. 2019; 95 (4): 8–23. 25. Заболеваемость всего населения России в 2020 году с диагнозом, установленным впервые в жизни: статистические материалы/ Е.Г. Котова, О.С. Кобякова, В.И. Стародубов, Г.А. Алексан - дрова, Н.А. Голубев, и др. М.: ЦНИИОИЗ Минздрава России. – 2021. – 143 с 26. Schneider L, Hanifin J, Boguniewicz M, Eichenfield LF, Spergel JM, Dakovic R, Paller AS. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr 68 Dermatol. 2016 Jul;33(4):388-98. doi: 10.1111/pde.12867. Epub 2016 Jun 7. PMID: 27273433; PMCID: PMC5649252. 27. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012 Dec;67(12):1475-82. doi: 10.1111/all.12049. Epub 2012 Oct 29. PMID: 23106343. 28. van der Hulst AE, Klip H, Brand PL. Risk of developing asthma in young children with atopic eczema: a systematic review. J Allergy Clin Immunol. 2007 Sep;120(3):565-9. doi: 10.1016/j.jaci.2007.05.042. Epub 2007 Jul 26. PMID: 17655920. 29. Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018 Jan;78(1):54-61.e1. doi: 10.1016/j.jaad.2017.08.002. Epub 2017 Oct 7. PMID: 29017738. 30. Illi S, von Mutius E, Lau S, Nickel R, Niggemann B, Sommerfeld C, Wahn U; Multicenter Allergy Study Group. The pattern of atopic sensitization is associated with the development of asthma in childhood. J Allergy Clin Immunol. 2001 Nov;108(5):709- 14. doi: 10.1067/mai.2001.118786. PMID: 11692093. 31. Yang L, Fu J, Zhou Y. Research Progress in Atopic March. Front Immunol. 2020 Aug 27;11:1907. doi: 10.3389/fimmu.2020.01907. PMID: 32973790; PMCID: PMC7482645; 32. Tsuge M, Ikeda M, Matsumoto N, Yorifuji T, Tsukahara H. Current Insights into Atopic March. Children (Basel). 2021 Nov 19;8(11):1067. doi: 10.3390/children8111067. PMID: 34828780; PMCID: PMC8620020; 33. Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: Many trajectories, many pathways. J Allergy Clin Immunol. 2019 Jan;143(1):46-55. doi: 10.1016/j.jaci.2018.11.006. Epub 2018 Nov 17. PMID: 30458183. 34. Aw M, Penn J, Gauvreau GM, Lima H, Sehmi R. Atopic March: Collegium Internationale Allergologicum Update 2020. Int Arch Allergy Immunol. 2020;181(1):1- 10. doi: 10.1159/000502958. Epub 2019 Oct 8. PMID: 31593946. 35. Spergel JM. Epidemiology of atopic dermatitis and atopic march in children. Immunol Allergy Clin North Am. 2010 Aug;30(3):269-80. doi: 10.1016/j.iac.2010.06.003. PMID: 20670812. 36. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol. 2018 Feb;120(2):131-137. doi: 10.1016/j.anai.2017.10.037. Erratum in: Ann Allergy Asthma Immunol. 2018 Mar 9;: PMID: 29413336; PMCID: PMC5806141. 37. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about 69 atopic dermatitis. J Allergy Clin Immunol. 2006 Jul;118(1):209-13. doi: 10.1016/j.jaci.2006.04.043. Epub 2006 Jun 9. PMID: 16815157. 38. Illi S, von Mutius E, Lau S, Nickel R, Grüber C, Niggemann B, Wahn U; Multicenter Allergy Study Group. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. J Allergy Clin Immunol. 2004 May;113(5):925-31. doi: 10.1016/j.jaci.2004.01.778. PMID: 15131576. 39. Anto JM, Bousquet J, Akdis M, Auffray C, Keil T, Momas I, Postma DS, Valenta R, Wickman M, Cambon-Thomsen A, Haahtela T, Lambrecht BN, Lodrup Carlsen KC, Koppelman GH, Sunyer J, Zuberbier T, Annesi-Maesano I, Arno A, Bindslev-Jensen C, De Carlo G, Forastiere F, Heinrich J, Kowalski ML, Maier D, Melén E, Smit HA, Standl M, Wright J, Asarnoj A, Benet M, Ballardini N, Garcia-Aymerich J, Gehring U, Guerra S, Hohmann C, Kull I, Lupinek C, Pinart M, Skrindo I, Westman M, Smagghe D, Akdis C, Andersson N, Bachert C, Ballereau S, Ballester F, Basagana X, Bedbrook A, Bergstrom A, von Berg A, Brunekreef B, Burte E, Carlsen KH, Chatzi L, Coquet JM, Curin M, Demoly P, Eller E, Fantini MP, von Hertzen L, Hovland V, Jacquemin B, Just J, Keller T, Kiss R, Kogevinas M, Koletzko S, Lau S, Lehmann I, Lemonnier N, Mäkelä M, Mestres J, Mowinckel P, Nadif R, Nawijn MC, Pellet J, Pin I, Porta D, Rancière F, Rial-Sebbag E, Saeys Y, Schuijs MJ, Siroux V, Tischer CG, Torrent M, Varraso R, Wenzel K, Xu CJ. Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes. J Allergy Clin Immunol. 2017 Feb;139(2):388-399. doi: 10.1016/j.jaci.2016.12.940. PMID: 28183433. 40. Атопический дерматит: рекомендации для практических врачей. Российский согласительный национальный документ по атопическому дерматиту. Под ред. P.M. Хаитова, А.А. Кубановой. М.: Фармакус Принт, 2002. 192 с. 41. Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019 Aug;123(2):144-151. doi: 10.1016/j.anai.2019.04.020. Epub 2019 Apr 26. PMID: 31034875.] 42. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta DermVenereol. 1980;92(Suppl):44–47. 43. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, Berger TG, Bergman JN, Cohen DE, Cooper KD, Cordoro KM, Davis DM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Williams HC, Elmets CA, Block J, Harrod CG, Smith Begolka W, Sidbury R. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010. Epub 2013 Nov 27. 70 PMID: 24290431; PMCID: PMC4410183. 44. Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH, Fosse N, Gáspár K, Gerbens L, Gieler U, Girolomoni G, Gregoriou S, Mortz CG, Nast A, Nygaard U, Redding M, Rehbinder EM, Ring J, Rossi M, SerraBaldrich E, Simon D, Szalai ZZ, Szepietowski JC, Torrelo A, Werfel T, Flohr C. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022 Sep;36(9):1409-1431. doi: 10.1111/jdv.18345. PMID: 35980214. 45. Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Werfel T, Zeng J, Huang X, Hu X, Hendrickson BA, Ladizinski B, Chu AD, Silverberg JI. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21. Erratum in: Lancet. 2021 Jun 19;397(10292):2336. Erratum in: Lancet. 2021 Aug 28;398(10302):746. PMID: 34023009]. 46. Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010 Dec;63(6):949-72; quiz 973-4. doi: 10.1016/j.jaad.2010.02.062. PMID: 21093660. 47. Arbes SJ Jr, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005 Aug;116(2):377-83. doi: 10.1016/j.jaci.2005.05.017. PMID: 16083793. 48. Клиническая дерматовенерология: в 2 т. / под ред. Ю.К. Скрипкина, Ю.С. Бутова. – М.: ГЭОТАР-Медиа, 2009. – т.II. – 928 с. 49. Wang V, Boguniewicz J, Boguniewicz M, Ong PY. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021 Jan;126(1):3-12. doi: 10.1016/j.anai.2020.08.002. Epub 2020 Aug 7. PMID: 32771354; PMCID: PMC7411503] 50. Fedenko E, Elisyutina O, Shtyrbul O, Pampura A, Valenta R, Lupinek C, Khaitov M. Microarray-based IgE serology improves management of severe atopic dermatitis in two children. Pediatr Allergy Immunol. 2016 Sep;27(6):645-9. doi: 10.1111/pai.12572. Epub 2016 May 27. PMID: 27029871. 51. Sampson HA, Albergo R. Comparison of results of skin tests, RAST, and double-blind, 71 placebo-controlled food challenges in children with atopic dermatitis. J Allergy Clin Immunol. 1984 Jul;74(1):26-33. doi: 10.1016/0091-6749(84)90083-6. PMID: 6547461. 52. Darsow U, Laifaoui J, Kerschenlohr K, Wollenberg A, Przybilla B, Wüthrich B, Borelli S Jr, Giusti F, Seidenari S, Drzimalla K, Simon D, Disch R, Borelli S, Devillers AC, Oranje AP, De Raeve L, Hachem JP, Dangoisse C, Blondeel A, Song M, Breuer K, Wulf A, Werfel T, Roul S, Taieb A, Bolhaar S, Bruijnzeel-Koomen C, Brönnimann M, Braathen LR, Didierlaurent A, André C, Ring J. The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study. Allergy. 2004 Dec;59(12):1318-25. doi: 10.1111/j.1398- 9995.2004.00556.x. PMID: 15507101. 53. Roehr CC, Reibel S, Ziegert M, Sommerfeld C, Wahn U, Niggemann B. Atopy patch tests, together with determination of specific IgE levels, reduce the need for oral food challenges in children with atopic dermatitis. J Allergy Clin Immunol. 2001 Mar;107(3):548-53. doi: 10.1067/mai.2001.112849. PMID: 11240959. 54. Аллергология и иммунология: национальное руководство / Под ред. Хаитова Р.М., Ильиной Н.И. – М.: ГЭОТАР-Медиа, 2009. 55. Cartledge N, Chan S. Atopic Dermatitis and Food Allergy: A Paediatric Approach. Curr Pediatr Rev. 2018;14(3):171-179. doi: 10.2174/1573396314666180613083616. PMID: 29895253. 56. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, Hofmaier S, Aalberse RC, Agache I, Asero R, Ballmer-Weber B, Barber D, Beyer K, Biedermann T, Bilò MB, Blank S, Bohle B, Bosshard PP, Breiteneder H, Brough HA, Caraballo L, Caubet JC, Crameri R, Davies JM, Douladiris N, Ebisawa M, EIgenmann PA, FernandezRivas M, Ferreira F, Gadermaier G, Glatz M, Hamilton RG, Hawranek T, Hellings P, Hoffmann-Sommergruber K, Jakob T, Jappe U, Jutel M, Kamath SD, Knol EF, Korosec P, Kuehn A, Lack G, Lopata AL, Mäkelä M, Morisset M, Niederberger V, NowakWęgrzyn AH, Papadopoulos NG, Pastorello EA, Pauli G, Platts-Mills T, Posa D, Poulsen LK, Raulf M, Sastre J, Scala E, Schmid JM, Schmid-Grendelmeier P, van Hage M, van Ree R, Vieths S, Weber R, Wickman M, Muraro A, Ollert M. EAACI Molecular Allergology User's Guide. Pediatr Allergy Immunol. 2016 May;27 Suppl 23:1-250. doi: 10.1111/pai.12563. PMID: 27288833. 57. Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards. J Am Acad Dermatol. 2016 Feb;74(2):288-94. doi: 10.1016/j.jaad.2015.09.062. Epub 2015 Dec 11. PMID: 26685719. 72 58. Oranje AP, Stalder JF, Taïeb A, Tasset C, de Longueville M. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol. 1997 Feb;8(1):28-34. doi: 10.1111/j.1399-3038.1997.tb00139.x. PMID: 9260216. 59. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012 Jan;67(1):99-106. doi: 10.1111/j.1398- 9995.2011.02719.x. Epub 2011 Sep 27. PMID: 21951293. 60. Spielman SC, LeBovidge JS, Timmons KG, Schneider LC. A Review of Multidisciplinary Interventions in Atopic Dermatitis. J Clin Med. 2015 May 21;4(5):1156-70. doi: 10.3390/jcm4051156. PMID: 26239470; PMCID: PMC4470222. 61. Giam YC, Hebert AA, Dizon MV, Van Bever H, Tiongco-Recto M, Kim KH, Soebono H, Munasir Z, Diana IA, Luk DC. A review on the role of moisturizers for atopic dermatitis. Asia Pac Allergy. 2016 Apr;6(2):120-8. doi: 10.5415/apallergy.2016.6.2.120. Epub 2016 Apr 28. PMID: 27141486; PMCID: PMC4850335. 62. Breternitz M, Kowatzki D, Langenauer M, Elsner P, Fluhr JW. Placebo-controlled, double-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis: biophysical and clinical evaluation. Skin Pharmacol Physiol. 2008;21(1):39-45. doi: 10.1159/000111134. Epub 2007 Nov 19. PMID: 18025807. 63. Verallo-Rowell VM, Dillague KM, Syah-Tjundawan BS. Novel antibacterial and emollient effects of coconut and virgin olive oils in adult atopic dermatitis. Dermatitis. 2008 Nov-Dec;19(6):308-15. PMID: 19134433. 64. Simpson E, Dutronc Y. A new body moisturizer increases skin hydration and improves atopic dermatitis symptoms among children and adults. J Drugs Dermatol. 2011 Jul;10(7):744-9. PMID: 21720656. 65. Lindh JD, Bradley M. Clinical Effectiveness of Moisturizers in Atopic Dermatitis and Related Disorders: A Systematic Review. Am J Clin Dermatol. 2015 Oct;16(5):341-59. doi: 10.1007/s40257-015-0146-4. PMID: 26267423. 66. Miller DW, Koch SB, Yentzer BA, Clark AR, O'Neill JR, Fountain J, Weber TM, Fleischer AB Jr. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-tomoderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol. 2011 May;10(5):531-7. PMID: 21533301. 67. Grimalt R, Mengeaud V, Cambazard F; Study Investigators' Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled 73 study. Dermatology. 2007;214(1):61-7. doi: 10.1159/000096915. PMID: 17191050. 68. Msika P, De Belilovsky C, Piccardi N, Chebassier N, Baudouin C, Chadoutaud B. New emollient with topical corticosteroid-sparing effect in treatment of childhood atopic dermatitis: SCORAD and quality of life improvement. Pediatr Dermatol. 2008 NovDec;25(6):606-12. doi: 10.1111/j.1525-1470.2008.00783.x. PMID: 19067864. 69. Lucky AW, Leach AD, Laskarzewski P, Wenck H. Use of an emollient as a steroidsparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol. 1997 Jul-Aug;14(4):321-4. doi: 10.1111/j.1525-1470.1997.tb00968.x. PMID: 9263319. 70. Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008 Jan;22(1):73-82. doi: 10.1111/j.1468-3083.2007.02351.x. PMID: 18181976. 71. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderateto-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009 Dec;8(12):1106-11. PMID: 20027938. 72. Hou M, Sun R, Hupe M, Kim PL, Park K, Crumrine D, Lin TK, Santiago JL, Mauro TM, Elias PM, Man MQ. Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms. Exp Dermatol. 2013;22(3):210-215. 73. Otsuka A, Doi H, Egawa G, Maekawa A, Fujita T, Nakamizo S, Nakashima C, Nakajima S, Watanabe T, Miyachi Y, Narumiya S, Kabashima K. Possible new therapeutic strategy to regulate atopic dermatitis through upregulating filaggrin expression. J Allergy Clin Immunol. 2014;133(1):139-46.e1-10. 74. Мурашкин Н.Н., Опрятин Л.А., Епишев Р.В., Материкин А.И., Амбарчян Э.Т., Иванов Р.А., Савелова А.А., Нежведилова Р.Ю., Русакова Л.Л. Дефект филаггрина при атопическом дерматите: современные методы коррекции. Вопросы современной педиатрии. 2022;21(5):347–351. doi: https://doi.org/10.15690/vsp.v21i5.2452 75. Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Shimojo N, Tanaka A, Nakahara T, Nagao M, Hide M, Fujita Y, Fujisawa T, Futamura M, Masuda K, Murota H, Yamamoto-Hanada K; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, The Japanese Society of Allergology, The Japanese Dermatology Association. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020 Jul;69(3):356-369. doi: 10.1016/j.alit.2020.02.006. Epub 2020 Apr 4. 74 PMID: 32265116. 76. Darsow U, Wollenberg A, Simon D, Taïeb A, Werfel T, Oranje A, Gelmetti C, Svensson A, Deleuran M, Calza AM, Giusti F, Lübbe J, Seidenari S, Ring J; European Task Force on Atopic Dermatitis/EADV Eczema Task Force. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010 Mar;24(3):317-28. doi: 10.1111/j.1468-3083.2009.03415.x. Epub 2009 Aug 31. PMID: 19732254. 77. Chiang C, Eichenfield LF. Quantitative assessment of combination bathing and moisturizing regimens on skin hydration in atopic dermatitis. Pediatr Dermatol. 2009 May-Jun;26(3):273-8. doi: 10.1111/j.1525-1470.2009.00911.x. PMID: 19706087; PMCID: PMC2762386. 78. Devillers AC, Oranje AP. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006 Apr;154(4):579-85. doi: 10.1111/j.1365- 2133.2006.07157.x. PMID: 16536797. 79. Devillers AC, de Waard-van der Spek FB, Mulder PG, Oranje AP. Treatment of refractory atopic dermatitis using 'wet-wrap' dressings and diluted corticosteroids: results of standardized treatment in both children and adults. Dermatology. 2002;204(1):50-5. doi: 10.1159/000051810. PMID: 11834850. 80. Goodyear HM, Spowart K, Harper JI. 'Wet-wrap' dressings for the treatment of atopic eczema in children. Br J Dermatol. 1991 Dec;125(6):604. doi: 10.1111/j.1365- 2133.1991.tb14807.x. PMID: 1760370. 81. Dabade TS, Davis DM, Wetter DA, Hand JL, McEvoy MT, Pittelkow MR, el-Azhary RA, Davis MD. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol. 2012 Jul;67(1):100-6. doi: 10.1016/j.jaad.2011.06.025. Epub 2011 Oct 5. PMID: 21978575. 82. Nicol NH, Boguniewicz M. Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis. Immunol Allergy Clin North Am. 2017 Feb;37(1):123-139. doi: 10.1016/j.iac.2016.08.003. Epub 2016 Nov 1. PMID: 27886902. 83. Brenninkmeijer EE, Spuls PI, Lindeboom R, van der Wal AC, Bos JD, Wolkerstorfer A. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010 Oct;163(4):823-31. doi: 10.1111/j.1365-2133.2010.09858.x. PMID: 20491772. 84. Pels R, Sterry W, Lademann J. Clobetasol propionate--where, when, why? Drugs Today 75 (Barc). 2008 Jul;44(7):547-57. doi: 10.1358/dot.2008.44.7.1122221. PMID: 18806904. 85. Breneman D, Fleischer AB Jr, Kaplan D, Lebwohl M, Miller B, Pariser D, Rist T, Swinyer L, Liu Y, Foley V. Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream. J Drugs Dermatol. 2005 May-Jun;4(3):330-6. PMID: 15898289. 86. Feldman SR. Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005 May;66(3):154-71. doi: 10.1016/j.curtheres.2005.06.010. PMID: 24672120; PMCID: PMC3964525. Feldman S.R. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. CurrTher Res ClinExp. 2005; 66 (3): 154–171. 87. Datz B., Yawalkar S. A double-blind, multicenter trial of 0.05% halobetasol propionate ointment and 0.05% clobetasol 17-propionate ointment in the treatment of patients with chronic, localized atopic dermatitis or lichen simplex chronicus. J AmAcadDermatol. 1991; 25 (6 Pt 2): 1157–1160. 88. Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29: 501–503. 89. Ainley‐Walker PF, Patel L, David TJ. Side to side comparison of topical treatment in atopic dermatitis. Arch Dis Child 1998; 79: 149– 52. 90. Аллергология и иммунология под ред. Л.С. Намазовой-Барановой, А.А. Баранова, Р.М. Хаитова: Союз педиатров России и др. – М.: Изд-во «ПедиатрЪ», 2020.-с.200 (Практические рекомендации для педиатров)- 512 с. 91. Vanderploeg D.E. Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study. South Med J. 1976; 69 (7): 862–863. 92. Viglioglia P., Jones M.L., Peets E.A. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses. J Int Med Res. 1990; 18 (6): 460–467. 93. Queille C., Pommarede R., Saurat J.H. Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol. 1984; 1 (3): 246–253. 94. Cabrera M.E. Treatment of severe or resistant corticosteroid-responsive dermatoses with Diprolene cream. J Int Med Res. 1984; 12 (3) :163–169. 95. Lodolo J.C. Diprolene cream in the treatment of severe or resistant corticosteroidresponsive dermatoses. J Int Med Res. 1984; 12 (2): 114–120. 76 96. Peterkin G.A., Morley W.N., Chalmers D. Triamcinolone and fluocinolone acetonide ointments in atopic eczema. BrMed J. 1962; 1 (5289): 1392. 97. Hanifin J.M. Atopic dermatitis. Special clinical complications. Postgrad Med. 1983;74(3):188–193, 196–199. 98. Cadmus S.D., Sebastian K.R., Warren D. et al. Efficacy and patient opinion of wet‐ wrap dressings using 0.1% triamcinolone acetonide ointment vs cream in the treatment of pediatric atopic dermatitis: A randomized split‐ body control study. PediatrDermatol. 2019; 36 (4): 437–441. 99. Wolkerstorfer A., Strobos M.A., Glazenburg E.J. et al. Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis. J Am Acad Dermatol. 1998; 39 (2 Pt 1): 226–231. 100. Bleehen S.S., Chu A.C., Hamann I. et al. Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once- daily vehicle cream application versus twice-daily treatment. Br J Dermatol. 1995; 133 (4): 592–597. 101. Rubio-Gomis E, Martinez-Mir I, Morales-Olivas FJ, Martorell-Aragones A, Palop-Larrea V, Bernalte-Sesé A, Cerda-Mir JC, Polo-Martín P, Febrer I, Aranda-Grau L, Llosa-Cortes I, Tejedor-Sanz MJ, Julia-Benito JC, Alvarez-de-Laviada-Mulero T, Planelles-Cantarino MV, Apolinar-Valiente E, Loriente-Tur M, Abella-Bazataqui AM, Alvarez-Gonzalez I, Morales-Carpi C, Burches-Greus ME, Ferrer-Bautista AB, Felix-Toledo R, MarmaneuLaguia D, Garcia-Martinez VE, Beltran-Marques MA, Rodriguez-Gracia B. Fluticasone in mild to moderate atopic dermatitis relapse: A randomized controlled trial. Allergol Immunopathol (Madr). 2018 Jul-Aug;46(4):378-384. doi: 10.1016/j.aller.2017.12.001. Epub 2018 Jan 17. PMID: 29373242. 102. Белоусова Т.А., Горячкина М.В. Опыт применения флутиказона пропионата (Кутивейт) в терапии псориаза, экземы и атопического дерматита. Эффективная фармакотерапия. 2010; 9: 24–29. 103. Berth-Jones J, Damstra RJ, Golsch S et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. Br Med J 2003; 326: 1367 104. Prakash A., Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders.Drugs. 1998;55(1):145– 163. 105. Vernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad 77 Dermatol. 1991; 24 (4): 603–607. 106. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: mometasone furoate study group. Int J Dermatol. 1999; 38 (8): 604–606. 107. Томилова А.Ю., Торшхоева Р.М., Геворкян А.К., Вознесенская Н.И. Эффективность и безопасность применения мометазона фуроата при атопическом дерматите у детей. Педиатрическая фармакология 2009; 6 (4): 123–127. 108. Шаипов Т.С., Мазитова Л.П. Применение мометазона фуроата при лечении атопического дерматита у детей. Педиатрическая фармакология. 2007; 4 (5): 41–44. 109. Ненашева Н.М. Особенности атопического дерматита у взрослых пациентов Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. 2012; (3): 6–15. 110. Lane A.T. Efficacy and safety of topical steroids in paediatric atopic dermatitis. J Eur Acad Dermatol Venereol. 1997; 8: S24–S27. 111. Faergemann J., Christensen O., Sjövall P. et al. An open study of efficacy and safety of long‐ term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2000; 14 (5): 393–396. 112. Haneke E. The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid. J DermatolTreatm. 1992; 3 (Suppl.2): 13–15. 113. Luger T.A. Balancing efficacy and safety in the management of atopic dermatitis: the role of methylprednisolone aceponate. J EurAcadDermatolVenereol. 2011; 25 (3): 251–258. 114. Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, Arcangeli F. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis. Allergy. 2007 Feb;62(2):184-9. 115. Кондратьева Ю.С., Кархова В.В. Опыт применения 0,1% метилпреднизолона ацепоната в комплексной терапии стероидчувствительных дерматозов. Вестник дерматологии и венерологии 2016; 1: 93–98. 116. Чикин В.В. Метилпреднизолона ацепонат и декспантенол в топической терапии больных атопическим дерматитом. Вестник дерматологии и венерологии 2014; 5: 112– 116. 117. Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double- 78 blind, controlled study. Br J Dermatol. 2008 Apr;158(4):801-7. 118. Veien N.K., Hattel T., Justesen O. et al. Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis. J Int Med Res. 1984; 12 (5):310–313. 119. Rajka G., Verjans H.L. Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis. J Int Med Res. 1986; 14 (2): 85–90. 120. Abramovits A, Oquendo M. Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis. SKINmed. 2010; 8: 72–79. 121. Koopmans B., Lasthein Andersen B., Mork N.J. et al. Multicentre randomized doubleblind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily. J Dermatol Treat. 1995;6 (2): 103–106. 122. Saki N, Jowkar F, Alyaseen S. et al. Comparison of sertaconazole 2% cream versus hydrocortisone 1% ointment in the treatment of atopic dermatitis. J Dermatolog Treat. 2013;24 (6): 447–449. 123. Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2002; 109 (3): 547–555. 124. Matheson R., Kempers S., Breneman D. et al. Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects. J Drugs Dermatol. 2008; 7 (3): 266– 271. 125. Sears H.W., Bailer J.W., Yeadon A. Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis. Clin Ther. 1997; 19 (4): 710–719. 126. Игнатьев Д.В., Кочергин Н.Г. Местные кортикостероиды в практике врачадерматолога. Особенности гидрокортизона бутирата (локоида). Дерматология. Приложение к журналу ConsiliumMedicum. 2007; 1: 50–54. 127. Udompataikul M., Limpa-o-Vart D. Comparative trial of 5% dexpanthenol in water-in-oil formulation with 1% hydrocortisone ointment in the treatment of childhood atopic dermatitis: a pilot study. J Drugs Dermatol. 2012; 11 (3): 366–374. 128. Canpolat F, Erkoçoğlu M, Tezer H, Kocabaş CN, Kandi B. Hydrocortisone acetate alone or combined with mupirocin for atopic dermatitis in infants under two years of age - a randomized double blind pilot trial. Eur Rev Med Pharmacol Sci. 2012 Dec;16(14):1989- 93. PMID: 23242727. 129. Giannetti A, Laria G, Seidenari S. L'idrocortisone 17-butirrato (0,1 percento) verso l'idrocortisone acetato (1 percento) nella dermatite atopica. Studio controllato a doppio 79 cieco in 20 bambini [Hydrocortisone-17-butyrate (0.1 percent) versus hydrocortisone acetate (1 percent) in atopic dermatitis. Controlled double-blind study of 20 children]. Minerva Pediatr. 1981 Jun 30;33(12):597-600. Italian. PMID: 7022158. 130. Сергеев Ю.В., Иванов О.Л., Новиков Д.К. и др. Атопический дерматит: современная диагностика и лечение. Иммунопатология, аллергология, инфектология. 2001; 4: 39– 131. Lassus A. Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children. Int J Dermatol. 1984; 23 (8): 565–566. 132. Торопова Н.П., Черкасова Л.А., Платонова И.Н. и др. Опыт применения препарата «Афлодерм» (алклометазона дипропионат) в детской дерматологической практике. Российский журнал кожных и венерических болезней. 2003; 3: 39–40. 133. Panja S.K., Gangopadhaya A.K., Sharma S.D. A randomised, double-blind comparison of alclometasone dipropionate 0.05% cream in atopic dermatitis and other dermatoses. Indian J Dermatol. 1988; 33 (1): 1–4. 134. Макарова И.В., Гайдук И.М., Жиглинская О.В и др. Применение 0,05% крема алклометазона дипропионата в терапии атопического дерматита у детей раннего возраста. Вопросы современной педиатрии. 2004; 3 (4): 84–87. 135. Короткий Н.Г., Тихомиров А.А., Гамаюнов Б.Н. Оценка клинической эффективности современного стероида алклометазона дипропионата (Афлодерма) в наружной терапии атопического дерматита у детей. Клиническая дерматология и венерология. 2007; 6: 24–31. 136. Ashcroft D.M., Dimmock P., Garside R. et al. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. 2005; 330 (7490): 516. 137. Ruzicka T., Bieber T., Schöpf E. et al. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med. 1997; 337 (12): 816–821. 138. Reitamo S., Wollenberg A., Schöpf E. et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000; 136 (8): 999– 1006. 139. Chen S.L., Yan J., Wang F.S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J DermatologTreat. 2010; 21 (3): 144–156. 140. Bornhövd E.C., Burgdorf W.H., Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory skin diseases. CurrOpinInvestig Drugs. 2002; 3 (5): 80 708– 712. 141. Lubbe J. Klinische Erfahrungen mit topischen Calcineurininhibitoren in der Praxis. Hautarzt. 2003; 54 (5): 432–439. 142. Reitamo S., Ortonne J.P., Sand C. et al. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005; 152 (6): 1282–1289. 143. Patel R.R., Vander Straten M.R., Korman N.J. The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis. Arch Dermatol. 2003; 139 (9): 1184– 1186. 144. Wollenberg A., Sidhu M.K., Odeyemi I. et al. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2008; 159 (6): 1322–1330. 145. Healy E., Bentley A., Fidler C., Chambers C. Cost-effectiveness of tacrolimus ointment in adults and children with moderate and severe atopic dermatitis: twice-weekly maintenance treatment vs. standard twicedaily reactive treatment of exacerbations from a third party payer (U.K. National Health Service) perspective. Br J Dermatol 2011; 164 (2): 387–395. 146. Reitamo S., Mandelin J., Rubins A. et al. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. Int J Dermatol. 2009; 48 (4): 348–355. 147. Reitamo S., Rustin M., Harper J. et al. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients. Br J Dermatol. 2008; 159 (4): 942–951. 148. Mandelin J.M., Remitz A., Virtanen H.M. et al. A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years. J Dermatolog Treat. 2010; 21 (3): 167–170. 149. Mandelin J., Remitz A., Virtanen H.M. et al. One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial. Acta Derm Venereol. 2010; 90 (2): 170–174. 150. Boguniewicz M., Fiedler V.C., Raimer S. et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. PediatricTacrolimus Study Group. J AllergyClinImmunol 1998; 102: 637–644. 151. Елисютина О.Г., Феденко Е.С., Штырбул О.В., Ниязов Д.Д. Применение такролимуса у больных атопическим дерматитом среднетяжелого и тяжелого 81 течения. Первый клинический опыт в России. Российский аллергологический журнал 2011; 6: 68–76. 152. Прошутинская Д.В., Бутарева М.М., Иноятова Л.А. Новые возможности терапии атопического дерматита у детей и взрослых. Вестник дерматологии и венерологии 2013; 3: 78–82. 153. Самцов А.В., Сухарев А.В., Патрушев А.В., Бондарь О.И. Клиническая эффективность, безопасность и переносимость 0,1% мази такролимус при лечении атопического дерматита средней и тяжелой степени тяжести. Вестник дерматологии и венерологии 2012; 2: 71–77. 154. Самцов А.В., Сухарев А.В., Патрушев А.В. Лечение атопического дерматита: преимущества такролимуса перед топическими кортикостероидами. Эффективная фармакотерапия 2014; 19: 4–10. 155. Meurer M., Fölster-Holst R., Wozel G. et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205 (3): 271–277. 156. Wahn U., Bos J., Goodfield M. et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002; 110 (1 Pt 1): 1– 8. 157. Ho V.C., Gupta A., Kaufmann R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr 2003; 142 (2): 155– 162. 158. Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002; 46 (4): 495–504. 159. Langley R.G., Eichenfield L.F., Lucky A.W. et al. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children withatopic dermatitis. Pediatr Dermatol. 2008; 25 (3): 301–307. 160. Luger T., van Leent E.J., Graeber M. et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol. 2001; 144 (4): 788–794. 161. Eichenfield L.F., Thaci D., de Prost Y. et al. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. Dermatology 2007; 11: 3–17. 162. Reda A.M., Elgendi A., Ebraheem A.I, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019; 30 (4): 366–373. 163. Кубанов А.А., Петровский Ф.И. Активированный пиритион цинка (Скин-кап). 82 Механизмы действия. Клиническое применение. Вестник дерматологии и венерологии, 2009; 5: 35–42. 164. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Скин-Кап в терапии атопического дерматита у детей (по результатам Российского многоцентрового исследования КАДЕТ). Российский Аллергологический Журнал 2007; 2: 75–81. 165. Фассахов Р.С., Пампура А.Н., Коростовцев Д.С. и др. Эффективность и безопасность активированного цинк пиритиона (скин-кап) в лечении атопического дерматита у детей (результаты Российского многоцентрового исследования). Вестник педиатрической фармакологии и нутрициологии 2006; 3 (6): 28–31. 166. Нейродерматозы. В кн.: Кожные и венерические болезни: Руководство для врачей. В двух томах. – 2-е изд., перераб. и доп. – Т.2/ Под ред. Ю.К. Скрипкина и В.Н. Мордовцева, - М.: Медицина, 1999. – С.9–49. 167. Matterne U, Böhmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. Cochrane atabase Syst Rev. 2019 Jan 22;1(1):CD012167. doi: 10.1002/14651858.CD012167.pub2 168. Misery L, Belloni Fortina A, El Hachem M, Chernyshov P, von Kobyletzki L, Heratizadeh A, Marcoux D, Aoki V, Zaniboni MC, Stalder JF, Eichenfield LF. A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient-Education Network in Dermatology (OPENED) task force. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):787-796 169. Yoshida H., Niimura M., Ueda H. et al. Clinical evaluation of ketotifen syrup on atopic dermatitis: a comparative multicenter double-blind study of ketotifen and clemastine. Ann Allergy. 1989; 62 (6): 507–512. 170. Григорьева И., Сергеев А., Манина И., Кудрявцева Е. Иммунопатология и биохимические основы атопических состояний. Врач. 2012; 4: 86–91. 171. Морозова С.В., Лусс Л.В. Хлоропирамин: современные аспекты применения. Вопросы современной педиатрии. 2007; 6 (1): 137–140. 172. Горячкина М.В., Белоусова Т.А. Хлоропирамин: клинические аспекты применения. Русский медицинский журнал. Аллергология. 2014; 24: 1785–1789. 173. Петрова К.С., Петрова Г.А. Хлоропирамин (Супрастин) – современные аспекты применения в терапии аллергодерматозов. Русский медицинский журнал. Фармакотерапия. 2014; 8: 617–620. 174. Ревякина В.А. Антигистаминные препараты в клинической практике. Русский 83 медицинский журнал. Аллергология. 2014; 11: 854–856. 175. Behrendt H., Ring J. Histamine, antihistamines and atopic eczema. Clin Exp Allergy. 1990;20 (Suppl 4): 25–30. 176. Ильченко С.И., Науменко Н.В., Пинаева Н.Л. Сравнительная оценка эффективности применения препарата Фенкарол при атопическом дерматите у детей дошкольного возраста Клінічна імунологія. Алергологія. Інфектологія. № 9– 10 (78–79) 2014 177. Parisi GF, Leonardi S, Ciprandi G, Corsico A, Licari A, Miraglia Del Giudice M, Peroni D, Salpietro C, Marseglia GL. Antihistamines in children and adolescents: A practical update. Allergol Immunopathol (Madr). 2020 Nov-Dec;48(6):753-762 178. Langeland T., Fagertun H.E., Larsen S. Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study. Allergy. 1994; 49 (1): 22– 26. 179. Monroe E.W. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther. 1992; 14 (1): 17–21. 180. Попова И.С., Матушевская Е.В., Свирщевская Е.В. Двойное слепое плацебо– контролируемое исследование эффективности и переносимости кларотадина при атопическом дерматите. Русс. Мед. Журн. Дерматология, Венерология. 2001; 9 (4): 477–483. 181. Hannuksela M., Kalimo K., Lammintausta K. et al. Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults. Ann Allergy. 1993; 70 (2): 127–133. 182. La Rosa M., Ranno C., Musarra I. et al. Double-blind study of cetirizine in atopic eczema in children. Ann Allergy 1994; 73 (2): 117–122. 183. Павлова О.В. Опыт применения цетиризина (аллертека) в терапии больных атопическим дерматитом и экземой. Вестник дерматологии и венерологии 2005; (4): 41–43. 184. Макарова И.В., Жиглинская О.В., Михайлова Е.А., Сухорукова В.Г. Сравнительная эффективность препаратов цетиризина дженерика (производство Эгис, Венгрия) и оригинального в форме капель в комплексной терапии атопического дерматита у детей раннего возраста. Вопросы современной педиатрии. 2007; 6 (3): 85–88. 185. Самсыгина Г.А. Аллергические болезни у детей. – М.: ГЭОТАР-Медиа, 2019. – 272 с. 186. Делягин В.М., Уразбагамбетов А. Применение Cупрастинекса (левоцетиризина) при атопии у детей и подростков. Русский медицинский журнал. Педиатрия 2012; (16): 828–830. 84 187. Елисютина О.Г., Феденко Е.С., Федоскова Т.Г., Лусс Л.В. Эффективность терапии левоцетиризином больных с аллергодерматозами. Росс. Аллергол. Журнал, 2012,5: 69- 75 188. Simons FE; Early Prevention of Asthma in Atopic Children (EPAAC) Study Group. Safety of levocetirizine treatment in young atopic children: An 18-month study. Pediatr Allergy Immunol. 2007 Sep;18(6):535-42. doi: 10.1111/j.1399-3038.2007.00558.x. Epub 2007 Jun 11. PMID: 17561929]. 189. Тамразова О.Б. Патогенетическая терапия детей, страдающих тяжелыми формами атопического дерматита. Русский медицинский журнал. Педиатрия. 2013; (2): 108– 114. 190. Нажмутдинова Д.К., Швец О.И. Левоцетиризин: перезагрузка. Русский медицинский журнал. Дерматология. 2011; 21: 1324–1326. 191. Камаев А.В., Трусова О.В., Камаева И.А. Зуд при атопическом дерматите у детей: известные механизмы и возможности его долгосрочного контроля. Русский медицинский журнал. 2015; 3: 142–146. 192. Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015;100(3):122-131 193. Motola D, Donati M, Biagi C, et al. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol Drug Saf. 2017;26(10):1164- 1171. doi:10.1002/pds.4246. 194. Zhang MY, Dugbartey GJ, Juriasingani S, Sener A. Hydrogen Sulfide Metabolite, Sodium Thiosulfate: Clinical Applications and Underlying Molecular Mechanisms. Int J Mol Sci. 2021 Jun 16;22(12):6452. doi: 10.3390/ijms22126452. PMID: 34208631; PMCID: PMC8235480. 195. Abe K., Kimura H. The possible role of hydrogen sulfide as an endogenous neuromodulator. J. Neurosci. 1996;16:1066–1071. doi: 10.1523/JNEUROSCI.16-03- 01066.1996. 196. Трофимова И.Б., Константиновская Е.Е., Фаттяхетдинова З.Г. Повышение эффективности патогенетической терапии псориаза с помощью инфузионных сукцинатсодержащих растворов. Клиническая дерматология и венерология, 2015, № 5, с. 141-145 197. Данилова А.А. Общие подходы к терапии экземы в практике врача-интерниста. Лечащий врач. 2011; (8): 94-7. 198. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract. 2020 85 Jan;8(1):91-101. doi: 10.1016/j.jaip.2019.06.044. Epub 2019 Aug 29. PMID: 31474543; PMCID: PMC7395647. 199. Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018 Apr;78(4):733-740.e11. doi: 10.1016/j.jaad.2017.09.074. Epub 2017 Dec 6. PMID: 29032119. 200. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, Chamlin SL, Cooper KD, Feldman SR, Hanifin JM, Krol A, Margolis DJ, Paller AS, Schwarzenberger K, Silverman RA, Simpson EL, Tom WL, Williams HC, Elmets CA, Block J, Harrod CG, Begolka WS, Eichenfield LF; American Academy of Dermatology. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. // J Am Acad Dermatol. 2014 Aug;71(2):327-49. 201. Schmitt J, Schakel K, Folster-Holst R, Bauer A, Oertel R, Augustin M, et al. Prednisolone vs cyclosporin for severe adult eczema: an investigator-initiated doubleblind placebo-controlled multicenter trial. // Br J Dermatol 2010; 162:661-8. 202. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis), part II. // J Eur Acad Dermatol Venereol 2012;26:1176-93 203. Pua VS, Barnetson RS. Recent developments in the treatment of adult atopic dermatitis. Australas J Dermatol. 2006 May;47(2):84-9. doi: 10.1111/j.1440-0960.2006.00237.x. PMID: 16637800. 204. Akhavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin. Dermatol. 2003; 21: 225–40 205. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med 1976;84:304–15. 206. Cronstein BN, Kimmel SC, Levin RI, et al. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992;89:9991–5 207. Abramovits W. A clinician's paradigm in the treatment of atopic dermatitis. J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S70-7. doi: 10.1016/j.jaad.2005.04.032. PMID: 15968266. 208. Heddle RJ, Soothill JF, Bulpitt CJ, et al. Combined oral and nasal beclomethasone dipropionate in children with atopic eczema: a randomized controlled trial. Br Med J (Clin Res Ed) 1984 Sep 15; 289 (6446): 651-4 24. 86 209. La Rosa M, Musarra I, Ranno C, et al. A randomized, double-blind, placebo-controlled crossover trial for systemic flunisolide in the treatment of children with severe atopic dermatitis. Curr Therap Res 1995; 56: 720-6 25. 210. Galli E, Chini L, Moschese V, et al. Methylprednisolone bolus: a novel therapy for severe atopic dermatitis. Acta Paediatr 1994 Mar; 83 (3): 315-7 211. Кудрявцева А. В., Балаболкин И. И., Геппе Н. А., Ксензова Л. Д. Лечение системными глюкокортикостероидами детей с тяжелым течением атопического дерматита. Российский форум «Педиатрия Санкт-Петербурга: Опыт, Инновации, Достижения». Сентябрь 2010, с. 126. 212. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, Czarnecka-Operacz M, Schäfer T, SchmidGrendelmeier P, Simon D, Szalai Z, Szepietowski JC, Taïeb A, Torrelo A, Werfel T, Ring J; European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018 May;32(5):657-682 213. Galli E, Fortina AB, Ricci G, Maiello N, Neri I, Baldo E, Berti I, Bonamonte D, Capra L, Carboni E, Carello R, Caroppo F, Cavagni G, Chinellato I, Cipriani F, Comberiati P, Diociaiuti A, Di Lernia V, Duse M, Filippeschi C, Giannetti A, Giovannini M, Licari A, Marseglia GL, Pace M, Patrizi A, Pajno GB, Peroni D, Villani A, Eichenfield L. Narrative review on the management of moderate-severe atopic dermatitis in pediatric age of the Italian Society of Pediatric Allergology and Immunology (SIAIP), of the Italian Society of Pediatric Dermatology (SIDerP) and of the Italian Society of Pediatrics (SIP). Ital J Pediatr. 2022 Jun 14;48(1):95. 214. Hagenström K, Sauer K, Mohr N, Dettmann M, Glaeske G, Petersen J, Garbe C, Steimle T, Augustin M. Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis. Clin Epidemiol. 2021 Jul 22;13:593-602 215. Czech W., Brautigam M., Weidinger G., Schöpf E. Body weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653–659. 87 216. Harper J.I., Ahmed I., Barclay G. et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000; 142: 52–58. 217. Granlund H., Erkko P., Remitz A. et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta DermVenereol 2001; 81: 22–27. 218. Zurbriggen B., Wuthrich B., Cachelin A.B. et al. Comparison of two formulations of cyclosporin A in the treatment of severe atopic dermatitis. A double-blind, single-centre, cross-over pilot study. Dermatology 1999; 198: 56–60. 219. Hijnen D.J., ten Berge O., Timmer-de Mik L.et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007; 21: 85–89. 220. Schmitt J., Schmitt N., Meurer M. Cyclosporin in the treatment of patients with atopic eczema a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21 (5): 606–619. 221. Amor K.T., Ryan K., Menter A. The use of cyclosporine in dermatology: Part I. J Am Acad Dermatol 2010; 63 (6): 925–946. 222. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A, Czarnecka-Operacz M, Schäfer T, SchmidGrendelmeier P, Simon D, Szalai Z, Szepietowski JC, Taïeb A, Torrelo A, Werfel T, Ring J; European Dermatology Forum (EDF), the European Academy of Dermatology and Venereology (EADV), the European Academy of Allergy and Clinical Immunology (EAACI), the European Task Force on Atopic Dermatitis (ETFAD), European Federation of Allergy and Airways Diseases Patients’ Associations (EFA), the European Society for Dermatology and Psychiatry (ESDaP), the European Society of Pediatric Dermatology (ESPD), Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS). Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018 Jun;32(6):850-878. doi: 10.1111/jdv.14888. PMID: 29878606. 223. El‐Khalawany MA, Hassan H, Shaaban D, Ghonaim N, Eassa B. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr 2013; 172: 351– 356 224. Deo M, Yung A, Hill S, Rademaker M. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014 Aug;53(8):1037-41 225. Taieb Y, Baum S, Ben Amitai D, Barzilai A, Greenberger S. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. J Dermatolog 88 Treat. 2019 May;30(3):240-244, Notaro ER, Sidbury R. Systemic Agents for Severe Atopic Dermatitis in Children. Paediatr Drugs. 2015 Dec;17(6):449-57 226. Samorano LP, Takaoka R, Zaniboni MC, Aoki V. Methotrexate for atopic dermatitis in adults: a prospective study from a reference center in Brazil. J Dtsch Dermatol Ges. 2021 Feb;19(2):294-296. doi: 10.1111/ddg.14414. PMID: 33586894. 227. Bracho-Borro M, Franco-Ruiz PA, Magaña M. The use of azathioprine in atopic dermatitis: A review. Dermatol Ther. 2022 Sep;35(9):e15665. doi: 10.1111/dth.15665. Epub 2022 Jul 10. PMID: 35751547. 228. Simpson E.L., Bieber T., Guttman-Yassky E. et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016; 375 (24): 2335–2348. 229. Blauvelt A., de Bruin-Weller M., Gooderham M. et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017; 389 (10086): 2287–2303. 230. de Bruin-Weller M., Thaçi D., Smith C.H. et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebocontrolled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. 231. Thaçi D., L Simpson E., Deleuran M. et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Dermatol Sci. 2019; 94 (2): 266–275. 232. Cork M.J., Eckert L., Simpson E.L. et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat. 2019 Jun 9:1–9. 233. Snast I., Reiter O., Hodak E. et al. Are biologics efficacious in atopic dermatitis? asystematic review and meta-analysis. Am J Clin Dermatol. 2018; 19 (2):145–165. 234. Wang F.P., Tang X.J., Wei C.Q. et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. J Dermatol Sci. 2018; 90 (2):190– 198. 235. Paller A.S., Siegfried E.C., Thaçi D. et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad 89 Dermatol. 2020; 83 (5): 1282–1293. 236. Paller A.S., Bansal A., Simpson E.L. et al. Clinically meaningful responses to dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: Post-hoc analyses from a randomized clinical trial. Am J Clin Dermatol. 2020; 21 (1): 119–131. 237. Simpson E.L., Paller A.S., Siegfried E.C. et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. JAMA Dermatol. 2020; 156 (1): 44–56. 238. Cork M.J., Thaçi D., Eichenfield L.F. et al. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020; 182 (1): 85–96. 239. Paller AS, Siegfried EC, Simpson EL, Cork MJ, Lockshin B, Kosloski MP, Kamal MA, Davis JD, Sun X, Pirozzi G, Graham NMH, Gadkari A, Eckert L, Ruddy M, Bansal A. A phase 2, open-label study of single-dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):464-475. doi: 10.1111/jdv.16928. Epub 2020 Nov 8. PMID: 32893393; PMCID: PMC7894166. 240. Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, DubostBrama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A; participating investigators. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140- 6736(22)01539-2. PMID: 36116481. 241. FDA. DUPIXENT® (dupilumab). HIGHLIGHTS OF PRESCRIBING INFORMATION. [Электронный ресурс] URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s044lbl.pdf Дата доступа 23.10.2022 242. Guttman-Yassky, Emma et al. ―Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.‖ Lancet (London, England) vol. 397,10290 (2021): 2151-2168. 243. Silverberg JI, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, Costanzo A, Rosmarin D, Lynde C, Liu J, Gamelli A, Zeng J, Ladizinski B, Chu AD, Reich K. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study 90 results. J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14. PMID: 34403658. 244. Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029. PMID: 35262646; PMCID: PMC8908226. 245. Thyssen J. Et al. Efficacy of Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Stratified Analysis From Three Phase 3 Trials by Key Baseline Characteristics. Presented at the 30th European Academy of Dermatology and Venereology Congress, 29 September–2 October 2021, EADV Virtual Congress 2. 246. Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021 Sep 1;157(9):1047- 1055. doi: 10.1001/jamadermatol.2021.3023. Erratum in: JAMA Dermatol. 2022 Feb 1;158(2):219. Erratum in: JAMA Dermatol. 2022 Feb 1;158(2):219. PMID: 34347860; PMCID: PMC8340015. 247. Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, Cameron MC, Myers DE, Clibborn C, DiBonaventura M. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021 Sep;35(9):1797- 1810. doi: 10.1111/jdv.17351. Epub 2021 Jun 12. PMID: 33991374; PMCID: PMC8453983. 248. Pereyra-Rodriguez JJ, Alcantara-Luna S, Domínguez-Cruz J, Galán-Gutiérrez M, RuizVillaverde R, Vilar-Palomo S, Armario-Hita JC. Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. Life (Basel). 2021 Sep 6;11(9):927. doi: 10.3390/life11090927. PMID: 34575076; PMCID: PMC8470048. 249. Silverberg JI, Hong HC, Thyssen JP, Calimlim BM, Joshi A, Teixeira HD, Collins EB, Crowell MM, Johnson SJ, Armstrong AW. Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis. Dermatol Ther (Heidelb). 2022 91 May;12(5):1181-1196. doi: 10.1007/s13555-022-00721-1. Epub 2022 Apr 18. PMID: 35435637; PMCID: PMC9110624. 250. Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, Kaszuba A, Kolodsick J, Yang FE, Gamalo M, Brinker DR, DeLozier AM, Janes JM, Nunes FP, Thyssen JP, Simpson EL. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020 Dec 1;156(12):1333-1343. doi: 10.1001/jamadermatol.2020.3260. PMID: 33001140; PMCID: PMC7527941. 251. Simpson EL, Lacour JP, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, King BA, Thyssen JP, Silverberg JI, Bieber T, Kabashima K, Tsunemi Y, Costanzo A, Guttman-Yassky E, Beck LA, Janes JM, DeLozier AM, Gamalo M, Brinker DR, Cardillo T, Nunes FP, Paller AS, Wollenberg A, Reich K. Baricitinib in patients with moderate-tosevere atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020 Aug;183(2):242-255. doi: 10.1111/bjd.18898. Epub 2020 Mar 5. PMID: 31995838. 252. Bieber T, Thyssen JP, Reich K, Simpson EL, Katoh N, Torrelo A, De Bruin-Weller M, Thaci D, Bissonnette R, Gooderham M, Weisman J, Nunes F, Brinker D, Issa M, Holzwarth K, Gamalo M, Riedl E, Janes J. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021 Feb;35(2):476-485. doi: 10.1111/jdv.16948. Epub 2020 Oct 6. PMID: 32926462. 253. Thyssen JP, Buhl T, Fernández-Peñas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Ständer S. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611. doi: 10.1007/s13555-021-00577- x. Epub 2021 Jul 18. PMID: 34275122; PMCID: PMC8484387. 254. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, Bieber T, Thyssen JP, Yosipovitch G, Flohr C, Magnolo N, Maari C, Feeney C, Biswas P, Tatulych S, Valdez H, Rojo R. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020 Jul 25;396(10246):255-266. doi: 10.1016/S0140-6736(20)30732-7. PMID: 32711801. 255. Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, Biswas P, Valdez H, DiBonaventura M, Nduaka C, Rojo R. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. 92 JAMA Dermatol. 2020 Aug 1;156(8):863-873. doi: 10.1001/jamadermatol.2020.1406. PMID: 32492087; PMCID: PMC7271424. 256. Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, Gubelin W, Simpson EL, Valenzuela F, Criado PR, Lebwohl MG, Feeney C, Khan T, Biswas P, DiBonaventura M, Valdez H, Cameron MC, Rojo R. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022 Jan;86(1):104-112. doi: 10.1016/j.jaad.2021.05.075. Epub 2021 Aug 17. PMID: 34416294. 257. Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, Yao Z, Takahashi H, Barbarot S, Feeney C, Zhang F, DiBonaventura M, Rojo R, Valdez H, Chan G. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial. JAMA Dermatol. 2021 Oct 1;157(10):1165-1173. doi: 10.1001/jamadermatol.2021.2830. Erratum in: JAMA Dermatol. 2021 Oct 1;157(10):1246. PMID: 34406366; PMCID: PMC8374743. 258. Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021 Mar 25;384(12):1101- 1112. doi: 10.1056/NEJMoa2019380. PMID: 33761207. 259. Simpson EL, Silverberg JI, Nosbaum A. et al. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. Am J Clin Dermatol. 2021 Sep;22(5):693-707. doi: 10.1007/s40257-021-00618-3. Epub 2021 Aug 18. Erratum in: Am J Clin Dermatol. 2021 Nov;22(6):905. PMID: 34406619; PMCID: PMC8370859. 260. Nogueira M, Torres T. Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib. Dermatol Pract Concept. 2021 Oct 1;11(4):e2021145. doi: 10.5826/dpc.1104a145. PMID: 35024237; PMCID: PMC8648435. 261. Jung M.Y., Chung J.Y., Lee H.Y. et al. Antibiotic susceptibility of Staphylococcus aureus in atopic dermatitis: current prevalence of methicillin-resistant Staphylococcus aureus in Korea and treatment strategies. Ann Dermatol. 2015; 27 (4): 398–403. 262. Lübbe J. Secondary infections in patients with atopic dermatitis. Am J ClinDermatol 2003; 4 (9): 641–654. 263. Масюкова С.А., Гладько Е.В., Тарасенко Г.Н. и др. Фузидиевая кислота в лечении пиодермитов и аллергодерматозов, осложненных бактериальной инфекцией. Вестник дерматологии и венерологии. 2007; 6: 54–57. 264. Дворянкова Е.В., Корсунская И.М., Захарова А.Б., Жуковский Р.О. Атопический дерматит, осложненный вторичной инфекцией: подходы к терапии. Эффективная фармакотерапия. 2011; 26: 74–76. 265. Ларькова И.А. Эффективная терапия атопического дерматита у детей, осложненного вторичной инфекцией. Медицинский совет. 2016; 1: 162–167. 266. Матушевская Е.В., Свирщевская Е.В. Атопический дерматит в практике врачадерматовенеролога: рациональный выбор терапии. Русский медицинский журнал. 2013; 21 (8): 410–412. 267. Gong J.Q., Lin L., Lin T. et al. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol 2006; 155: 680–687. 268. Lever R, Hadley K, Downey D, Mackie R. Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy. Br J Dermatol 1988; 119:189–198. 269. Альбанова В. Наружное лечение атопического дерматита. Врач. 2006; 2: 76–78. 270. Батыршина С.В., Хаертдинова Л.А. Концепция местной терапии больных атопическим дерматитом. Практическая медицина. 2009; 35 (3): 41–45. 271. Wachs G.N., Maibach H.I. Co-operative double-blind trial of an antibiotic ⁄ corticoid combination in impetiginized atopic dermatitis. Br J Dermatol 1976; 95: 323–328. 272. Schuttelaar M.L., Coenraads P.J. A randomized, double-blind study to assess the efficacy of addition of tetracycline to triamcinolone acetonide in the treatment of moderate to severe atopic dermatitis. J EurAcadDermatolVenereol 2008; 22: 1076–1082. 273. Васенова В.Ю., Бутов Ю.С. Применение Полькортолона ТС для лечения зудящих дерматозов, осложненных вторичной инфекцией. Русский медицинский журнал 2013; 21 (22): 1096–1098. 274. Скрипкин Ю.К., Хамаганова И.В. Опыт применения аэрозолей оксикорт и полькортолон ТС в лечении аллергических дерматозов, осложненных пиодермией. Вестник дерматологии и венерологии. 2004; 1: 42–43. 275. Ramsay C., Savoie J., Gilbert M. et al. The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate. J Eur Acad Dermatol Venereol 1996; 7 (Suppl. 1):S15–22. 276. Hjorth N., Schmidt H., Thomsen K. Fusidic acid plus betamethasone in infected or potentially infected eczema. Pharmatherapeutica 1985; 4: 126–131. 94 277. Тарасова М.В., Марина Т.В., Сорокина Е.А. и др. Целесообразность применения комбинированных топических глюкокортикостероидов в комплексной терапии атопического дерматита. Журнал научных статей Здоровье и образование в XXI веке. 2008; 10 (3): 383. 278. Кубанова А.А. Прошутинская Д.В., Текучева Л.В., Авдиенко И.Н. Интегральный подход к наружной терапии больных атопическим дерматитом. Вестник дерматологии и венерологии. 2010; 1: 20–26. 279. Ненашева Н.М. Особенности местной (наружной) терапии осложненного инфекцией атопического дерматита. РМЖ. 2015; 23 (19): 1159–1165. 280. Кунгуров Н.В., Кениксфест Ю.В., Кохан М.М. и др. Комбинированная наружная терапия осложненных дерматозов. Клиническая дерматология и венерология. 2005; 2: 33–37. 281. Шибаева Е.В., Пышкина Е.И. Наружная терапия инфицированных дерматозов: адекватный подход к выбору препарата // Эффективная фармакотерапия. 2013. № 1 (8). С. 10–15., 282. Кравченя С.С., Игонина И.А., Бакулев А.Л. Комбинированная наружная терапия атопического дерматита. Клиническая дерматология и венерология. 2011;9(1):41‑44 283. Шарова Н.М. Место Пимафукорта в поэтапном комплексном лечении атопического дерматита. // Дерматология. Приложение consilium medicum 2014; 2: 12-14 284. Хлебникова А.Н. Рациональная терапия инфицированных дерматозов. Эффективная фармакотерапия. 2013;40:22–7. 285. Niebuhr M., Mai U., Kapp A., Werfel T. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. ExpDermatol. 2008; 17 (11): 953–957. 286. Boguniewicz M., Sampson H., Leung S. et al. Effects of cefuroxime axetil on Staphylococcus aureus colonizing and superantigen production in atopic dermatitis. J Allergy Clin Immunol 2001; 108: 651–652. 287. Тренева М.С., Пампура А.Н. Стратегия выбора антибактериальных препаратов у детей с микробным инфицированием атопического дерматита. Практическая медицина. 2011; 3 (51): 136–139. 288. Boguniewicz M., Leung D.Y. Recent insights into atopic dermatitis and implications for management of infectious complications. J AllergyClinImmunol. 2010; 125 (1): 4–13. 289. Tognetti L., Martinelli C., Berti S. et al. Bacterial skin and soft tissue infections: review of the epidemiology, microbiology, aetiopathogenesis and treatment: a collaboration between dermatologists and infectivologists. J Eur Acad Dermatol Venereol. 2012; 26 95 (8): 931–941. 290. Petry V., Bessa G.R., Poziomczyck C.S. et al. Bacterial skin colonization and infections in patients with atopic dermatitis. An Bras Dermatol. 2012; 87 (5): 729–734. 291. Wollenberg A. Eczema herpeticum. Chem Immunol Allergy. 2012; 96: 89–95. 292. Niimura M., Nishikawa T. Treatment of eczema herpeticum with oral acyclovir. Am J Med.1988; 85 (2A): 49–52. 293. Монахов С. А., Коржачкина Н. Б., Олисова О. Ю. Узковолновая фототерапия 311 нм в лечении больных атопическим дерматитом. Российский журнал кожных и венерических болезней. 2012; 3: 25–27. 294. Majoie I.M., Oldhoff J.M., van Weelden H. et al. Narrowband ultraviolet B and mediumdose ultraviolet A1 are equally effective in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2009; 60: 77–84. 295. Reynolds N.J., Franklin V., Gray J.C. et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet. 2001; 357 (9273): 2012–2016. 296. Clayton T.H., Clark S.M., Turner D., Goulden V. The treatment of severe atopic dermatitis in childhood with narrowband ultraviolet B phototherapy. Clin Exp Dermatol. 2007; 32 (1): 28–33.Seccombe L., Wynne M.D., Clancy C. et al. A retrospective review of phototherapy in children, at a tertiary paediatric dermatology unit. Photodermatol Photoimmunol Photomed. 2021; 37 (1): 34–38. 297. Gambichler T., Othlinghaus N., Tomi N.S. et al. Medium-dose ultraviolet (UV) A1 vs. narrowband UVB phototherapy in atopic eczema: a randomized crossover study. Br J Dermatol 2009; 160 (3): 652–658. 298. Bogaczewicz J., Malinowska K., Sysa-Jedrzejowska A., Wozniacka A. Medium-dose ultraviolet A1 phototherapy improves SCORAD index and increases mRNA expression of interleukin-4 without direct effect on human β defensin-1, interleukin-10, and interleukin-31. Int J Dermatol. 2016; 55 (7): e380–e385. 299. TzanevaS.,Seeber A., Schwaiger M. et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol. 2001; 45: 503–507. 300. Malinowska K., Wozniacka A., Bogaczewicz J. The impact of medium dose UVA1 phototherapy on pruritus, DLQI and SCORAD index in patients with atopic dermatitis. Postepy Dermatol Alergol. 2020; 37 (6): 962–967. 301. Abeck D., Schmidt T., Fesq H. et al. Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis. J Am Acad Dermatol. 2000; 42 (2 Pt 1): 254–257. 96 302. Pugashetti R., Lim H.W., Koo J. Broadband UVB revisited: is the narrowband UVB fad limiting our therapeutic options? J DermatologTreat. 2010; 21 (6): 326–330. 303. Tzaneva S., Kittler H., Holzer G. et al. 5-Methoxypsoralen plus ultraviolet (UV) A is superior to medium-dose UVA1 in the treatment of severe atopic dermatitis: a randomized crossover trial. Br J Dermatol. 2010; 162 (3): 655–660. 304. Garritsen F.M., Brouwer M.W., Limpens J., Spuls P.I. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol. 2014; 170 (3): 501–513. 305. Pérez-Ferriols A., Aranegui B., Pujol-Montcusí J.A. et al. Phototherapy in atopic dermatitis: a systematic review of the literature. Actas Dermosifiliogr. 2015; 106 (5): 387– 401. 306. Uetsu N., Horio T. Treatment of persistent severe atopic dermatitis in 113 Japanese patients with oral psoralen photo-chemotherapy. J Dermatol. 2003; 30 (6): 450–457. 307. Физическая и реабилитационная медицина. Национальное руководство. / Под ред. Г.Н. Пономаренко., М.: ГЭОТАР-Медиа, 2016 г. 688 с. 308. Частная физиотерапия:Учебное пособие / Под ред.Г.Н. Пономаренко. — М.: ОАО «Издательство «Медицина», 2005, 744 с. 309. Patrizi A., Raone B., Ravaioli G.M. Management of atopic dermatitis: safety and efficacy of phototherapy. ClinCosmetInvestig Dermatol. 2015; 8: 511–520. 310. Dogra S., Mahajan R.; Indian Association of Dermatologists, Venereologists and Leprologists. Phototherapy for atopic dermatitis. Indian J Dermatol VenereolLeprol. 2015; 81 (1): 10–15. 311. Кубанова А.А., Самсонов В.А., Волнухин В.А. и др. Терапия больных псориазом, атопическим дерматитом и витилиго узкополосным средневолновым ультрафиолетовым излучением с длиной волны 311 нм. Медицинская технология № ФС-2006/250 от 15 августа 2006 года. Вестник дерматологии и венерологии 2008; 3: 17–20. 312. Thompson K.G., Kim N. Distinguishing myth from fact: photocarcinogenesis and phototherapy.DermatolClin. 2020; 38 (1): 25–35. 313. Baltás E, Csoma Z, Bodai L, Ignácz F, Dobozy A, Kemény L. Treatment of atopic dermatitis with the xenon chloride excimer laser. J Eur Acad Dermatol Venereol. 2006 Jul;20(6):657-660. doi: 10.1111/j.1468-3083.2006.01495.x. PMID: 16836491. 314. Kurosaki Y, Tsurumachi M, Kamata Y, Tominaga M, Suga Y, Takamori K. Effects of 308 nm excimer light treatment on the skin microbiome of atopic dermatitis patients. Photodermatol Photoimmunol Photomed. 2020 May;36(3):185-191. 97 doi:10.1111/phpp.12531. Epub 2020 Jan 24. PMID: 31880842. 315. Nisticò SP, Saraceno R, Capriotti E, Felice CD, Chimenti S. Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. Photomed Laser Surg. 2008 Feb;26(1):14-18. doi:10.1089/pho.2007.2116. PMID: 18248156. 316. Wollenschläger I, Hermann J, Ockenfels HM. UVB-308-nm- (NUVB-) Therapiemittels Excimer-Laser bei atopischer Dermatitis und weiteren inflammatorischen Dermatosen [Targeted UVB-308 nm (NUVB) therapy with excimer laser in the treatment of atopic dermatitis and other inflammatory dermatoses]. Hautarzt. 2009 Nov;60(11):898-906. German. doi: 10.1007/s00105-009-1828-8. PMID: 19711024. 317. Bussmann C., Bockenhoff A., Henke H. et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006; 118: 1292–1298. 318. Darsow U., Forer I., Ring J. Allergen-specific immunotherapy in atopic eczema. Curr Allergy Asthma Rep 2011; 11: 277–283. 319. Bae J.M., Choi Y.Y., Park C.O. et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013; 132: 110–117. 320. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982; 107: 597–602. 321. Glover M.T., Atherton D.J. A double-blind controlled trial of hyposensitization to Dermatophagoidespteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22: 440–446. 322. Zachariae H., Cramers M., Herlin T.etal. Non-specific immunotherapy and specific hyposensitization in severe atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985; 114: 48–54. 323. Елисютина О.Г., Феденко Е.С. Место специфической иммунотерапии в лечении больных атопическим дерматитом, осложненным рецидивирующей пиодермией. Физиология и патология иммунной системы. Физиология и патология иммунной системы. 2006;(8): С.15. 324. Novak N., BieberT., Hoffmann M. et al. Efficacy and safety of subcutaneous allergenspecific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012; 130: 925– 931 e4. 325. Pajno G.B., Caminiti L., Vita D. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J 98 Allergy Clin Immunol 2007; 120: 164–170. 326. Qin Y.E., Mao J.R., Sang Y.C., Li W.X. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoidesfarinae drops in patients with atopic dermatitis. Int J Dermatol 2014; 53: 650–655. 327. Liu L., Guo D., Liang Q. et al. The efficacy of sublingual immunotherapy with Dermatophagoidesfarinae vaccine in a murine atopic dermatitis model. Clin Exp Allergy 2015; 45: 815–822. 328. Атопический дерматит/ В.И. Альбанова, А.Н. Пампура. – М: ГЭОТАР-Медиа, 2014. – 128 с 329. Система поддержки принятия врачебных решений. Аллергология иммунология: Клинические протоколы лечения / Составители: Д. С. Фомина, В. А. Ревякина, И. В. Данилычева [и др.] – М.: ГБУ «НИИОЗММ ДЗМ», 2021. – 110 с. 330. Roduit C., Frei R., Loss G. et al. Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol 2012; 130: 130– 136 e5. 331. Perkin M.R., Logan K., Tseng A. et al. Randomized trial of introduction of allergenic foods in breast-fed infants. N Engl J Med 2016; 374: 1733–1743. 332. Prell C., Koletzko B. Breastfeeding and Complementary Feeding. DtschArztebl Int. 2016;113(25):435–444. 333. Vandenplas Y., Al-Hussaini B., Al-Mannaei K. et al. Prevention of Allergic Sensitization and Treatment of Cow's Milk Protein Allergy in Early Life: The Middle-East Step-Down Consensus. Nutrients. 2019 Jun 26;11(7). 334. Gruber C. Probiotics and prebiotics in allergy prevention and treatment: future prospects. Exp Rev Clin Immunol 2012; 8: 17 –19. 335. Cuello-Garcia C.A., Brozek J.L., Fiocchi A. et al. Probiotics for the prevention of allergy: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2015; 136: 952–961. 336. PanduruМ., Panduru N.M., Sălăvăstru C.M., Tiplica G.S. Probiotics and primary prevention of atopic dermatitis: a meta-analysis of randomized controlled studies. J Eur Acad Dermatol Venereol 2015; 29 (2): 232–242. 337. Muraro A., Halken S., Arshad S.H. et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy 2014; 69: 590–601. 338. Kantor R., Kim A., Thyssen J.P., Silverberg J.I. Association of atopic dermatitis with smoking: a systematic review and meta-analysis. J Am Acad Dermatol 2016; 75: 1119– 1125 e1. 99 339. Kathuria P., Silverberg J.I. Association of pollution and climate with atopic eczema in US children. Pediatr Allergy Immunol 2016; 27: 478–485. 340. Morgenstern V., Zutavern A., Cyrys J. et al. Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children. Am J Respir Crit Care Med 2008; 177: 1331–1337. 341. Hidaka T., Ogawa E., Kobayashi E.H. et al. The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin. Nat Immunol 2017; 18: 64–73. 342. Sugita K., Akdis C.A. Recent developments and advances in atopic dermatitis and food allergy. Allergol Int. 2020; 69 (2): 204–214. 343. Staab D., Diepgen T.L., Fartasch M. et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ. 2006; 332:933–938. 344. Lambert J., Bostoen J., Geusens B. et al. A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results. Arch Dermatol Res. 2011; 303:57–63. 345. Kupfer J., Gieler U., Diepgen T.L. et al. Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial. J PsychosomRes. 2010; 68 (4):353–358. 346. Staab D., von Rueden U., Kehrt R. et al. Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol. 2002; 13:84–90. 347. Kiriyama T., Sugiura H., Uehara M. Residual washing detergent in cotton clothes: a factor of winter deterioration of dry skin in atopic dermatitis. J Dermatol. 2003; 30:708– 712. 348. Schmid-Wendtner M.H., Korting H.C. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006; 19: 296–302. 349. Simpson E., Trookman N.S., Rizer R.L. et al. Safety and tolerability of a body wash and moisturizer when applied to infants and toddlers with a history of atopic dermatitis: results from an open-label study. Pediatr Dermatol. 2012; 29:590–597. 350. Hon K.L., Leung T.F., Wong Y. et al. A survey of bathing and showering practices in children with atopic eczema. Clin Exp Dermatol. 2005; 30:351–354. 351. Wollenberg A, Vogel S, Renner ED. Impfungen bei Neurodermitis und anderen chronisch entzündlichen Hauterkrankungen [Vaccinations with atopic dermatitis and other chronic inflammatory skin diseases]. Hautarzt. 2010 Nov;61(11):985-93; quiz 994. German. doi: 10.1007/s00105-010-2019-3. PMID: 20967404.